Recombinant Monkey Antibody (mAb2.5B) is capable of binding to HIV-1 gp120, expressed in mammalian cells.
Figure 1 Competing the capturing of virions by RhMAbs with human MAbs.
SF162 virions were first incubated with the human anti-HIV-1 Env MAbs 447 (anti-V3), 830A (anti-V2), 2909 (anti-quaternary epitope), 860-55 (anti-parvovirus, used as a negative internal control), or soluble CD4 and then added to wells coated with the indicated MAbs (x axis). Inhibition of capturing is represented as the percent reduction in virion capturing (y axis) compared to the capturing of SF162 virions that were not preincubated with human MAbs or sCD4.
Robinson, J. E., Franco, K., Elliott, D. H., Maher, M. J., Reyna, A., Montefiori, D. C., ... & Stamatatos, L. (2010). Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIVSF162P4. Journal of virology, 84(7), 3443-3453.
Figure 2 Role of the KV dipeptide in V2 on MAb neutralizing activities.
The lysine at position 158 (position 160, based on the HxB2 numbering) in the V2 loop of the SF162 Env was altered to alanine (V159A). The neutralizing susceptibilities of the corresponding mutant viruses to the RhMAbs 2.2G, 2.3E, 2.5B, and the human MAb 2909 were determined.
Robinson, J. E., Franco, K., Elliott, D. H., Maher, M. J., Reyna, A., Montefiori, D. C., ... & Stamatatos, L. (2010). Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIVSF162P4. Journal of virology, 84(7), 3443-3453.
Figure 3 Effect of V2 loop NLGSs on the neutralizing activity of RhMAbs and MAb 2909.
The V2 glycosylation sites (154, 186, and 195) were eliminated from the SF162 Env by mutating either the asparagines to glutamines or the serines to alanines. The amino acid sequence of the SF162. V2 loop is shown (numbering is based on SF162). The N-linked glycosylation sites are underlined.
Robinson, J. E., Franco, K., Elliott, D. H., Maher, M. J., Reyna, A., Montefiori, D. C., ... & Stamatatos, L. (2010). Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIVSF162P4. Journal of virology, 84(7), 3443-3453.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
PABL-380 | Human Anti-HIV-1 gp120 Recombinant Antibody (clone VRC06) | FC, Neut, FuncS | Human IgG |
PABL-520 | Human Anti-HIV-1 gp120 Recombinant Antibody (clone 44-VRC13.01) | Neut | Human IgG |
PABL-521 | Human Anti-HIV-1 gp120 Recombinant Antibody (PABL-521) | ELISA, Neut | Human IgG |
PABL-522 | Human Anti-HIV-1 gp120 Recombinant Antibody (clone 45-VRC01.H5.F-185917) | WB, FuncS | Human IgG |
PABL-523 | Human Anti-HIV-1 gp120 Recombinant Antibody (clone 8ANC131) | WB, FuncS | Human IgG |
There are currently no Customer reviews or questions for PABL-530. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.